NEFROLOGIA is a preeminent scientific journal published by the SOCIEDAD ESPAÑOLA DE NEFROLOGÍA DR. RAFAEL MATESANZ, specializing in cutting-edge research and clinical advancements in the field of nephrology. Established in 1981 and continuing through 2024, this journal serves as a crucial platform for nephrologists, researchers, and healthcare professionals to disseminate knowledge and foster dialogue on critical issues affecting kidney health. With its ISSN 0211-6995 and E-ISSN 1989-2284, NEFROLOGIA is indexed in prestigious databases, ranking #35 out of 81 in the Scopus Medicine Nephrology category, reflecting its significance within the medical community. Although it does not currently offer open access, the journal ensures wide accessibility and readership through institutional subscriptions. Researchers and clinicians are invited to contribute their findings and reviews, advancing our understanding and treatment of renal diseases. Through its commitment to high scholarly standards and impactful research, NEFROLOGIA remains a vital resource for those dedicated to improving kidney care and advancing nephrology sciences.

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

Vojnosanitetski Pregled is a distinguished open-access journal published by the Military Medical Academy in Serbia, with a commitment to disseminating high-quality research since 2002. Operating under the ISSN 0042-8450 and E-ISSN 2406-0720, it serves as a vital platform for scholars and practitioners in the fields of Medicine and Pharmacology, specifically addressing the unique challenges faced within military and veterans' health care. With a publication history spanning from 1949 to 2024, the journal has established itself as a reputable source of knowledge, currently holding a Q4 category ranking in both Medicine (miscellaneous) and Pharmacology (medical) as of 2023, and a Scopus rank of 240 out of 272, placing it in the 11th percentile. Vojnosanitetski Pregled aims to foster innovative research, facilitate collaboration among professionals, and contribute significantly to the ongoing development of military medical practices and policies. By prioritizing accessibility and engagement, this journal is an invaluable resource for researchers, healthcare professionals, and students eager to explore the intersection of military medicine and pharmacology.

NEPHROLOGY is a leading academic journal published by Wiley, dedicated to advancing research and discussions in the fields of Nephrology and Medicine. With an ISSN of 1320-5358, this journal has consistently demonstrated its significance and impact, reflecting a Q2 category ranking in both Medicine (miscellaneous) and Nephrology as of 2023. Covering a comprehensive range of topics since its inception in 1995, NEPHROLOGY provides a vital platform for researchers, practitioners, and students alike to explore the latest advancements, innovative treatments, and diverse challenges within the field. Although it does not operate under an open access model, the journal remains highly regarded, with a commendable Scopus rank of #27 out of 81 in Nephrology, positioning it in the 67th percentile among its peers. Located in the United Kingdom, NEPHROLOGY invites submissions that push the boundaries of knowledge, ultimately striving to enhance the understanding of renal health and disease.

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Aging Medicine, published by Wiley, is a pivotal open-access journal that has been at the forefront of research dedicated to the aging population since its inception in 2018. With a focus on both geriatric care and gerontology, the journal serves as a crucial resource for researchers, healthcare professionals, and students interested in understanding the complexities of aging and the related medical challenges. Although it holds a Q3 quartile ranking in the fields of Aging and Geriatrics and Gerontology according to the 2023 metrics, the journal continues to effectively disseminate valuable research and insights, helping to bridge gaps in knowledge and practice. With an E-ISSN of 2475-0360, it offers an open-access model that ensures broader accessibility to its published content, thus promoting collaboration and innovation across disciplines. As the journal converges towards 2024, it remains committed to evolving with the dynamics of aging research, making it a significant platform for the exchange of ideas and advancements in this essential field.

Welcome to the Cyprus Journal of Medical Sciences, a distinguished publication dedicated to the advancement of medical knowledge and research. Published by GALENOS PUBL HOUSE, this journal endeavors to uphold the highest standards of scientific inquiry in the medical field. With its ISSN 2149-7893 and E-ISSN 2536-507X, the journal serves as an essential resource for researchers, healthcare professionals, and students seeking to stay abreast of innovative findings and clinical practices. Although currently not listed under Open Access, this journal prioritizes rigorous peer review and the dissemination of impactful research aimed at driving improvements in medical science. The journal welcomes submissions that cover diverse areas within the medical realm, contributing to a more profound understanding of healthcare challenges and solutions. Join us in exploring the frontiers of medical sciences and contributing to a healthier future.

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

PANMINERVA MEDICA is a distinguished journal published by EDIZIONI MINERVA MEDICA, focusing on the multifaceted field of medicine since its inception in 1959. With an ISSN of 0031-0808 and an E-ISSN of 1827-1898, this journal is esteemed for its rigorous peer-review process and its contribution to clinical and experimental research across various domains of medicine. Based in Italy, it holds a commendable position in the 2023 Scopus rankings, where it is placed in the 84th percentile among general medicine journals, highlighting its relevance and scholarly impact. As a Q3 category journal in the medicine (miscellaneous) quartiles, PANMINERVA MEDICA is committed to disseminating high-quality research, fostering scientific dialogue, and advancing medical knowledge globally. While currently not offering open access, it serves as a vital resource for researchers, practitioners, and students seeking to stay at the forefront of medical advancements. The journal is poised to continue its tradition of excellence as it converges into 2024, ensuring robust discourse in healthcare and clinical practices.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.